Plus500 Expects to Meet Market Expectations as Quarterly Revenue Rises 11 Rosen Law Firm Reminds SES AI Corporation Investors of Class Action Deadline Seeking Counsel US Tariff Policy May Moderate Trade Representative Hints at Lower but Persistent Barriers Iran Never Bow Vow and Trump Counteroffer Rejection Intensify Middle East Tensions Raising Oil Supply Risks Novartis Raises Annual Outlook Signaling Confidence in Growth Trajectory US Fuel Prices Unlikely to Normalize This Year Even if Iran Conflict Ends Analysts Suggest PLMR Q1 2026 Earnings EPS Surpasses Estimates by 301 Amid Modest Stock Pullback VOYG Q1 2026 Earnings EPS Misses Estimates but Stock Surges 11 on Investor Optimism NiSource NI Q1 2026 Earnings EPS Falls Short But Stock Gains on Operational Resilience SVM Q1 2026 Earnings Modest EPS Beat Amid Silver Price Volatility CoreWeave CRWV Q1 2026 Earnings EPS Misses Estimates as Losses Widen Stock Declines AVR Q1 2026 Earnings Wider Than Expected Losses as PreRevenue Biotech Advances RingCentral RNG Surges 313 as Shares Approach Key Resistance Devon Energy DVN Edges Higher Amidst Volatile Energy Sector Key Levels to Watch PIMCO Dynamic Income Strategy Fund PDX Edges Lower Amidst Consolidation SuRo Capital Corp SSSS Slightly Lower as Shares Consolidate Near Key Support Maison Solutions MSS Edges Higher Key Levels to Watch Near 1 SpaceX IPO Hype Raises Questions on Valuation Logic STRW Q1 2026 Earnings Earnings Beat Estimates Despite Modest Stock Decline Humana HUM Holds Steady Near Support A Cautious Recovery in Managed Care WPM Q1 2026 Earnings EPS Surpasses Estimates by 23 VREX Q1 2026 Earnings Earnings Slightly Miss Estimates Amid Operational Margin Headwinds American Vanguard Corporation AVD Q3 2025 Earnings Deep EPS Miss and Steep Stock Decline Highlight Operational Headwinds Jiayin Group Q4 2024 Earnings Strong EPS Performance Amid Market Headwinds Aktis Oncology AKTS Q1 2026 Earnings EPS Misses Estimates as ClinicalStage Biotech Advances Pipeline NWFL Q1 2026 Earnings Strong EPS Beat Amid Challenging Environment SRPT Q1 2026 Earnings EPS Smashes Estimates by 1847 as Gene Therapy Execution Drives Profit Surprise